Livedoid vasculitis - Vasculitis Livedoid
Vasculitis Livedoid (Livedoid vasculitis) nexweşiyek çermî ya kronîk e ku bi giranî di jinên ciwan û navîn de tê dîtin. Yek akronîmek ku ji bo danasîna taybetmendiyên wê tê bikar anîn "Zirên purpurîk ên êşkêş ên bi şêwaza retîkuler a lemlateyên jêrîn" (PURPLE) ye. Ew bi hejmarek nexweşiyan re têkildar e, di nav de hîpertansiyona venoz a kronîk û varikozîtî.
☆ Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Ew dikare bi êşê re bibe.
References
Livedoid vasculopathy rewşek çermî ya nadir e ku bi ulcerên bi êş ên ku li ser lingên jêrîn vedigerin têne diyar kirin.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy rewşek çermî ya nadir e ku dibe sedema birînên dûbareyî li ser lingên jêrîn, li dû xwe birînên zer ku wekî atrofiya blanche têne zanîn dihêle. Digel ku sedema rastîn hîn jî ne diyar e, tê bawer kirin ku zêdebûna girêkbûna xwînê (hypercoagulability) faktora sereke ye, digel ku iltîhab rolek duyemîn dilîze. Faktorên ku beşdarî kelijandinê dibin wiha ne - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Di biopsîyan de, rewş di hundurê damaran de, stûrbûna dîwarên damaran, û birînbûnê nîşan dide. Dermankirin nêzîkatiyek pir-alî ye ku balê dikişîne ser pêşîlêgirtina tansiyonên xwînê bi dermanên mîna dermanên dijî-trombolê, ziravkerên xwînê, û terapiya fibrînolîtîk. Ji bo vê rewşa çerm dikare dermanên cûrbecûr werin bikar anîn - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy rewşek hindik e ku birîn li her du lingan çêdibin. Tê texmîn kirin ku çêbûna girêkên xwînê di damarên xwînê yên piçûk de ji ber zêdebûna kelijandinê û kêmbûna kelijandinê, ligel zirara xêzika damarê pêk tê. Ew di jinan de pirtir e, nemaze di navbera temenên 15 û 50 salî de. Dest ji cixarê berdan, lênihêrîna birînan, û karanîna dermanên mîna rijkerên xwînê û dermanên antîplatelet bi bandor bûne.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
